Effects of acute doses of oxiracetam in the scopolamine model of human amnesia.
The scopolamine model of amnesia has been used to test the pharmacodynamic efficacy of oxiracetam in 12 healthy volunteers. The subjects were divided into four experimental groups, according to a double-blind cross over incomplete randomized block design. After a baseline neuropsychological examination, each subject received in two separate sessions one of the following treatments, as acute oral doses: oxiracetam 800, 1600, 2400 mg or placebo. One hour after treatment scopolamine hydrobromide (0.5 mg) was given subcutaneously. The cognitive performance was tested before and 1, 2, 3 and 25 h after scopolamine administration. Scopolamine caused a deterioration of performance of verbal episodic memory, semantic memory and attention tests. In comparison to placebo, oxiracetam improved the overall test performance, with a statistically significant difference at the dose of 1600 mg on delayed recall of word lists, and showed dose-related antagonism of scopolamine-induced effects also on semantic memory and attention. The efficacy of an acute dose of oxiracetam in reducing scopolamine-induced cognitive impairment supports the potential usefulness of this pharmacological model of amnesia for studying the effects of cognition enhancers in humans.
Preda
L
L
Department of Neurology, University of Milan, San Raffaele Hospital, Italy.
Alberoni
M
M
Bressi
S
S
Cattaneo
C
C
Parini
J
J
Canal
N
N
Franceschi
M
M
D000328:Adult; D000647:Amnesia / Q000139:chemically induced / Q000523:psychology*; D001288:Attention / Q000187:drug effects; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects; D008570:Memory, Short-Term / Q000187:drug effects; D011939:Mental Recall / Q000187:drug effects; D009483:Neuropsychological Tests; D011619:Psychotropic Drugs / Q000494:pharmacology*; D011759:Pyrrolidines / Q000494:pharmacology*; D011932:Reading; D012601:Scopolamine / Q000037:antagonists & inhibitors* / Q000494:pharmacology
D011619:Psychotropic Drugs; D011759:Pyrrolidines; D012601:Scopolamine; C040619:oxiracetam